VANWIJNSBERGHE Samuël ,docteur en médecine
0893.826.789 · rovalta.com · 27/09/2026
VANWIJNSBERGHE Samuël ,docteur en médecine
Financial year 2024 · Closed on 31/12/2024
Overview
Identity
Source · BCE/KBOVANWIJNSBERGHE Samuël ,docteur en médecine is a Private company with limited liability incorporated in 2007. Its registered office is in Soignies.
- Legal situation
- Normal situation
- BCE/KBO no. / VAT
- BE 0893.826.789
- Incorporation
- 29/11/2007
- Legal form
- Private company with limited liability
- Registered office
- Rue Neuve 37
7060 Soignies · WallonieSee on map - Contributed capital
- 12 400,00 €
- Latest accounts
- 31/12/2024
Financials
Source · NBB, 13 filingsTrend over 13 financial years
| 2024 | 2023 | 2022 | 2021 | 2020 | |||||
|---|---|---|---|---|---|---|---|---|---|
| Income statement | |||||||||
| Gross margin | 12,3 k € | -21.5% | 15,7 k € | -32.5% | 23,2 k € | +89.2% | 12,3 k € | -20.3% | 15,4 k € |
| EBITDA | 11,8 k € | -22.3% | 15,2 k € | -31.9% | 22,3 k € | +81.6% | 12,3 k € | -18.0% | 15 k € |
| Operating result | 7,3 k € | -28.4% | 10,2 k € | +192% | 3,5 k € | +149% | -7,1 k € | -130% | -3,1 k € |
| Net result | 6,6 k € | -30.0% | 9,4 k € | +339% | 2,1 k € | +127% | -7,9 k € | -75.8% | -4,5 k € |
| Balance sheet | |||||||||
| Equity | -51,7 k € | +11.3% | -58,3 k € | +13.9% | -67,7 k € | +3.1% | -69,8 k € | -12.8% | -61,9 k € |
| Total assets | 36,8 k € | -20.2% | 46,2 k € | -15.0% | 54,3 k € | -14.3% | 63,4 k € | -22.0% | 81,2 k € |
| Cash | 998,7 € | -78.3% | 4,6 k € | +7.8% | 4,3 k € | +1654% | 243,8 € | -75.8% | 1 k € |
| Debts | 88,6 k € | -15.2% | 104,5 k € | -14.4% | 122 k € | -8.4% | 133,2 k € | -6.9% | 143,1 k € |
Valuation
Indicative valuation
As an indication, this company is worth
Board of directors
Source · NBB, accounts to 31/12/20241 active · 2 ended
Active mandates
| Director | Function | Mandate |
|---|---|---|
Samuel VANWIJNSBERGHE | Director |
Ended mandates
| Director | Function | Mandate |
|---|---|---|
SAMUEL VANWIJNSBERGHE | Manager | since 22/11/2007 |
Samuel VANWIJNSBERGHE | Manager |
Financials
Full financial information
Source · NBB| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|---|
| Type of account | Abridged model | Abridged model | Abridged model | Abridged model | Abridged model | Abridged model |
| Start of the financial year | 01/01/2024 | 01/01/2023 | 01/01/2022 | 01/01/2021 | 01/01/2020 | 01/01/2019 |
| Closing of the financial year | 31/12/2024 | 31/12/2023 | 31/12/2022 | 31/12/2021 | 31/12/2020 | 31/12/2019 |
| Length of the financial year | 12 months | 12 months | 12 months | 12 months | 12 months | 12 months |
| Filing date | 19/09/2025 | 02/01/2025 | 26/09/2023 | 30/09/2022 | 16/08/2021 | 30/09/2020 |
| General meeting | 30/06/2025 | 28/06/2024 | 30/06/2023 | 24/06/2022 | 30/06/2021 | 26/06/2020 |
| Currency of the financial year | EUR | EUR | EUR | EUR | EUR | EUR |
| NBB quality label | Satisfying controls | Satisfying controls | Satisfying controls | Satisfying controls | Satisfying controls | Satisfying controls |
Financial ratios
Source · NBBLooking for more information about this company?
Try for freeAnnual accounts filings
Source · NBB, 13 filings| Model | Closing | General meeting | Filed | Language | Document |
|---|---|---|---|---|---|
| Abridged model | 31/12/2024 | 30/06/2025 | 19/09/2025 | French | |
| Abridged model | 31/12/2023 | 28/06/2024 | 02/01/2025 | French | |
| Abridged model | 31/12/2022 | 30/06/2023 | 26/09/2023 | French | |
| Abridged model | 31/12/2021 | 24/06/2022 | 30/09/2022 | French | |
| Abridged model | 31/12/2020 | 30/06/2021 | 16/08/2021 | French | |
| Abridged model | 31/12/2019 | 26/06/2020 | 30/09/2020 | French | |
| Abridged model | 31/12/2018 | 28/06/2019 | 07/08/2019 | French | |
| Abridged model | 31/12/2017 | 29/06/2018 | 31/07/2018 | French | |
| Abridged model | 31/12/2016 | 08/12/2017 | 11/12/2017 | French | |
| Abridged model | 31/12/2014 | 26/06/2015 | 30/12/2015 | French | |
| Abridged model | 31/12/2013 | 27/06/2014 | 31/12/2014 | French | |
| Abridged model | 31/12/2010 | 24/06/2011 | 31/12/2011 | French | |
| Abridged model | 31/12/2008 | 26/06/2009 | 15/09/2009 | French |
Valuation
Indicative valuation
As an indication, this company is worth
between 0 € and 100 k€
The detail comes with the Business plan: low and high bounds, the valuation bridge for each financial year, transaction multiples by sector and size, group valuation and exports.
Indicative estimate based on public sector multiples and the filed annual accounts. It is neither a certified valuation nor financial or investment advice.
Directors & structure
Board of directors
Source · NBB, accounts to 31/12/20241 active · 2 ended
Active mandates
| Director | Function | Mandate |
|---|---|---|
Samuel VANWIJNSBERGHE | Director |
Ended mandates
| Director | Function | Mandate |
|---|---|---|
SAMUEL VANWIJNSBERGHE | Manager | since 22/11/2007 |
Samuel VANWIJNSBERGHE | Manager |
Ownership and network
Looking for more information about this company?
Try for freePublications
Similar companies
Similar companies
A company's peers, by sector and size, are included in the Business plan.
See the Business planTimeline
Timeline
- 2024Annual accounts 20246,6 k €↓
- 2023Annual accounts 20239,4 k €↑
- 2022Annual accounts 20222,1 k €↑
- 2021Annual accounts 2021-7,9 k €↓
- 2020Annual accounts 2020-4,5 k €↓
- 2019Annual accounts 20197,5 k €↑
- 2018Annual accounts 2018-198,9 €↓
- 2017Annual accounts 201717,9 k €↑
- 2016Annual accounts 201612,4 k €↑
- 2014Annual accounts 2014-26,4 k €↓
- 2013Annual accounts 2013-840 €↓
- 2010Annual accounts 201014,1 k €↓
- 2008Annual accounts 200826,9 k €
- 29/11/2007IncorporationPrivate company with limited liability
Company names
Source · NBB annual accounts, CBE| Name | Period | Source |
|---|---|---|
| VANWIJNSBERGHE Samuël ,docteur en médecineCurrent | CBE, tracked since 27/09/2026 | CBE |
| VANWIJNSBERGHE SAMUEL | accounts 2021 → 2024 | Accounts 2024 · 2025-00496755 |
Annual accounts date a value by the financial year it appears in. The CBE dates a change to the day, but its history has only been kept since 27/09/2026.